Eli Lilly and Company (LLY)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for LLY is $1,313.62, 4.5% above the last close of $1,257.03 on Oct 16, 2026; targets range from $939.03 to $1,481.54. Rating consensus: Buy.
Snapshot
- P/E42.2x
- P/E vs sector+49.8%
- P/E vs own+7.4%
- Target upside+4.5%
- ConsensusBuy
- Market cap$1.18T
- FCF yield+1.7%
- Insiders-$15.96M
- Earnings in13d
- News
Why it moved
Eli Lilly and Company (LLY) rose 0.4% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move is specific to LLY.
2 stories on the day (30-day average 4.4).
- Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
- A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $1,257.03 · +54.4% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendbullish
- Sector▲ +16.0%
- MAs20▲ 50▲ 100▲ 200▲
- Above MAs4 of 4 above
- MA20×50↑ in ~1d
- RSI69
- Support-2.3%
- Resistance—
- Off 52w high-1.8%
- Off ATH-1.8%
- 52w range$1,257.03
- Bollingerabove upper
- MACD10.36
- ATR+2.8%
- Volume1.0x
Analyst price targets
21 firms with a target in the last 12 months · last close $1,257.03 · as of Oct 16, 2026
Strong buy 6 · Buy 20 · Hold 3 · Sell 1 · Strong sell 1
Revenue and free cash flow
Q2 FY2026: Revenue +47.7% year over year, free cash flow 33.8% of revenue, operating margin 54.2%.
| Q2 FY2026 | Jun 30, 2026 | $22.97B | 7.94 | $7.76B | 85.8% | 54.2% | 30.9% |
| Q1 FY2026 | Mar 31, 2026 | $19.8B | 8.26 | $3.01B | 81.9% | 49.4% | 37.4% |
| Q4 FY2025 | Dec 31, 2025 | $19.29B | 7.39 | $678M | 82.5% | 46.6% | 34.4% |
| Q3 FY2025 | Sep 30, 2025 | $17.6B | 6.21 | $8.61B | 82.9% | 47.6% | 31.7% |
| Q2 FY2025 | Jun 30, 2025 | $15.56B | 6.29 | $1.28B | 84.3% | 45.1% | 36.4% |
| Q1 FY2025 | Mar 31, 2025 | $12.73B | 3.06 | -$1.6B | 82.5% | 41.7% | 21.7% |
| Q4 FY2024 | Dec 31, 2024 | $13.53B | 4.88 | $727M | 82.2% | 42.0% | 32.6% |
| Q3 FY2024 | Sep 30, 2024 | $11.44B | 1.07 | -$459M | 81.0% | 38.8% | 8.5% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 | | $1,257.03 | +0.4% | -1.8% | +4.5% | 42.2 | $1.18T | |
| 2 |  | $255.56 | +0.9% | -8.2% | +8.8% | 38.7 | $616B | |
| 3 |  | $285.42 | +0.7% | 0.0% | -1.4% | 80.4 | $504B | |
| 4 |  | $145.95 | +0.5% | -6.2% | +7.7% | 116.8 | $360B | |
| 5 |  | $432.49 | -0.4% | -2.6% | -7.5% | 26.9 | $234B | |
| 6 |  | $156.19 | -0.7% | -0.7% | +1.9% | — | $194B | |
| 7 |  | $29.58 | +0.5% | 0.0% | -7.1% | 39.1 | $169B | |
| 8 |  | $59.75 | -1.4% | -11.3% | +9.4% | 13.2 | $122B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.